The global investigational new drug CDMO market size is calculated at USD 5.61 billion in 2025 and is forecasted to reach around USD 10.26 billion by 2034, accelerating at a CAGR of 6.93% from 2025 to 2034. The North America market size surpassed USD 2.31 billion in 2024 and is expanding at a CAGR of 7.06% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Investigational New Drug CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Investigational New Drug CDMO Market Revenue and Volume, by Product
8.1.1 Small Molecules
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Large Molecules
8.1.2.1. Market Revenue and Volume Forecast
9.1. Investigational New Drug CDMO Market Revenue and Volume, by Service
9.1.1. Contract Development
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Contract Manufacturing
9.1.2.1. Market Revenue and Volume Forecast
10.1. Investigational New Drug CDMO Market Revenue and Volume, by End-use
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Biotech Companies
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product
11.1.2. Market Revenue and Volume Forecast, by Service
11.1.3. Market Revenue and Volume Forecast, by End-use
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product
11.1.4.2. Market Revenue and Volume Forecast, by Service
11.1.4.3. Market Revenue and Volume Forecast, by End-use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product
11.1.5.2. Market Revenue and Volume Forecast, by Service
11.1.5.3. Market Revenue and Volume Forecast, by End-use
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product
11.2.2. Market Revenue and Volume Forecast, by Service
11.2.3. Market Revenue and Volume Forecast, by End-use
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product
11.2.4.2. Market Revenue and Volume Forecast, by Service
11.2.4.3. Market Revenue and Volume Forecast, by End-use
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product
11.2.5.2. Market Revenue and Volume Forecast, by Service
11.2.5.3. Market Revenue and Volume Forecast, by End-use
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product
11.2.6.2. Market Revenue and Volume Forecast, by Service
11.2.6.3. Market Revenue and Volume Forecast, by End-use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product
11.2.7.2. Market Revenue and Volume Forecast, by Service
11.2.7.3. Market Revenue and Volume Forecast, by End-use
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product
11.3.2. Market Revenue and Volume Forecast, by Service
11.3.3. Market Revenue and Volume Forecast, by End-use
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product
11.3.4.2. Market Revenue and Volume Forecast, by Service
11.3.4.3. Market Revenue and Volume Forecast, by End-use
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product
11.3.5.2. Market Revenue and Volume Forecast, by Service
11.3.5.3. Market Revenue and Volume Forecast, by End-use
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product
11.3.6.2. Market Revenue and Volume Forecast, by Service
11.3.6.3. Market Revenue and Volume Forecast, by End-use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product
11.3.7.2. Market Revenue and Volume Forecast, by Service
11.3.7.3. Market Revenue and Volume Forecast, by End-use
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product
11.4.2. Market Revenue and Volume Forecast, by Service
11.4.3. Market Revenue and Volume Forecast, by End-use
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product
11.4.4.2. Market Revenue and Volume Forecast, by Service
11.4.4.3. Market Revenue and Volume Forecast, by End-use
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product
11.4.5.2. Market Revenue and Volume Forecast, by Service
11.4.5.3. Market Revenue and Volume Forecast, by End-use
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product
11.4.6.2. Market Revenue and Volume Forecast, by Service
11.4.6.3. Market Revenue and Volume Forecast, by End-use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product
11.4.7.2. Market Revenue and Volume Forecast, by Service
11.4.7.3. Market Revenue and Volume Forecast, by End-use
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product
11.5.2. Market Revenue and Volume Forecast, by Service
11.5.3. Market Revenue and Volume Forecast, by End-use
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product
11.5.4.2. Market Revenue and Volume Forecast, by Service
11.5.4.3. Market Revenue and Volume Forecast, by End-use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product
11.5.5.2. Market Revenue and Volume Forecast, by Service
11.5.5.3. Market Revenue and Volume Forecast, by End-use
12.1. Catalent, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lonza
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Recipharm AB
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Siegfried Holding AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Patheon Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Covance
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. IQVIA Holdings Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cambrex Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Charles River Laboratories International, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Syneous Health.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample